Cardiovascular Interventional Trials
The Following Trials at St. Francis Are Currently Recruiting Patients:
Does Co-registration of OCT and Angiography Reduce Geographic Miss of Stent Implantation? Richard Shlofmitz, M.D., PI. To determine whether the use of co-registration of optical coherence tomography and angiography reduces the incidence of geographic miss during coronary stenting.
Barostim neo®-Baroreflex ActivationTherapy® for Heart Failure-Timothy Vittorio, M.D., PI.To develop evidence for safety and effectiveness of Baroreflex Activation Therapy™ with the Barostim neo system in subjects with heart failure, defined as New York Heart Association functional Class III and left ventricular ejection fraction (LVEF) less than 35% despite being treated with the appropriate guideline directed heart failure therapy, excluding subjects eligible for or with a Cardiac Resynchronization Therapy (CRT) device.
Transcatheter Aortic Valve Replacement System: a US Pivotal Trial-George Petrossian, M.D., and Newell Robinson, M.D., PIs. The purpose of this trial is to determine the safety and effectiveness of the Direct Flow Medical Tran¬scatheter) Aortic Valve System in subjects with se-vere aortic stenosis who are candidates for TAVR.
Prevention of Death and Disability Due to Cardiovascular Disease in Diabetes-Nathaniel Reichek, M.D., PI.To assess the earliest manifestations of coronary atherosclerosis and abnormal myocardial composition in pre-diabetic and early diabetic patients using cardiovascular MRI and coronary CT angiography.
Functional Brain and Cardiac Imaging-Nathaniel Reichek, M.D., PI. To evaluate normal neural regulation of the heart and evaluate potential central abnormalities in heart failure and cardiomyopathies using MRI functional brain and cardiac imaging.
Advanced Cardiac Imaging in Detection of Cardiotoxicity of Cancer Chemotherapy-Nathaniel Reichek, M.D., and Bhoomi Mehrotra, M.D., PI. To determine whether myocardial strain imaging with echocardiographic and MRI methods and MRI tissue characterization can detect and quantitate early myocardial tissue injury caused by cancer chemotherapy with anthracyclines, trastuzumab or VegF inhibitors prior to a drop in left ventricular ejection fraction, in order to identify patients at highest risk of subsequent heart failure.
Please call (516) 562-6790 for more information about any of these trials.
Looking for Ways to Help?
St. Francis Hospital is blessed to have the support of a great many friends. Would you like to join in our efforts?
Best Nurses, Magnet Recognized
St. Francis Hospital has earned the coveted Magnet award for excellence in nursing.